BNY Mellon Research Growth Fund Q3 2025 Commentary

BNY Mellon Research Growth Fund (Class A at NAV) underperformed its benchmark, the Russell 1000® Growth Index (the “Index”), during the third quarter of 2025. Read more here.

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE Therapeutics, an interventional psychiatry network owned by NRx, today announced ...

Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH ...

Calamos Phineus Long/Short Fund Q3 2025 Commentary

Calamos Phineus Long/Short Fund rose 1.29% in Q3 amidst AI bubble risk. Discover our strategy to navigate market shifts and ...
The Manila Times on MSNOpinion

Behind diplomatic crisis, Japan’s economic slide

When Japan’s new prime minister Sanae Takaichi took office, she pledged to focus on economic improvement. After her Taiwan ...